18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma |
| |
Authors: | Elisa Rush Port MD Henry Yeung MD Mithat Gonen PhD Laura Liberman MD James Caravelli MD Patrick Borgen MD Steven Larson MD |
| |
Institution: | (1) Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021;(2) Department of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021;(3) Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021;(4) Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021 |
| |
Abstract: | Background The role of positron emission tomography (PET) scanning in determining the extent of disease in patients with breast cancer
has not been defined. We investigated the utility of 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET scanning compared with conventional imaging with computed tomographic scanning and bone scanning in determining
the extent of disease in patients with high-risk, operable breast cancer.
Methods This was a prospective study of patients who presented to Memorial Sloan-Kettering Cancer Center for operative treatment of
breast cancer. Eighty eligible patients were enrolled and underwent computed tomographic chest, abdomen, pelvis, and bone
scans, followed by FDG-PET. Changes in treatment based on scan findings were recorded by the operating surgeons. Imaging findings
were verified by biopsy or long-term follow-up.
Results Eight (10%) of 80 patients were found to have metastatic disease that was seen on both conventional imaging and PET. Four
additional patients (5%) had additional foci of disease on PET that affected treatment decisions. No patient had findings
on conventional imaging alone. Conventional imaging studies resulted in a higher number of findings that generated additional
tests and biopsies that ultimately had negative results (17% vs. 5% for PET). There was a statistically significant difference
in specificity for PET compared with conventional imaging (P = .01).
Conclusions Conventional imaging and PET were equally sensitive in detecting metastatic disease in patients with high-risk, operable breast
cancer, but PET generated fewer false-positive results. FDG-PET scanning should be further studied in this setting and considered
in the preoperative evaluation of selected patients with breast cancer. |
| |
Keywords: | D-glucose-positron emission tomography" target="_blank">18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography Breast cancer High risk Extent of disease |
本文献已被 PubMed SpringerLink 等数据库收录! |
|